Jason O'Byrne compensation by year
Caribou Biosciences Summary Compensation Table · the one fiscal year held| Component | FY2021 |
|---|---|
| Salary | $358,580 |
| Bonus | $227,775 |
| Option awards | $2,862,675 |
| Total | $3,449,030 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Caribou Biosciences, Inc. DEF 14A filed August 11, 2022, accession 0000950170-22-016847, and prior-year filings.
How this page was built: the Caribou Biosciences, Inc. filed document, accession 0000950170-22-016847. Every figure is read from that document and cited to the page and table it appears in. Filed August 11, 2022.
Insider transactions since the last proxy
3 Form 4 lines since the FY2021 proxy (filed August 11, 2022)current to 2026-11-21 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2024-02-20 | Grant or award | — | 33,000 | $0.00 | 59,224 |
| 2024-02-20 | Grant or award derivative | — | 153,000 | $0.00 | 153,000 |
| 2023-02-21 | Grant or award derivative | — | 131,000 | $0.00 | 131,000 |
The 3 most recent of 3 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
Caribou Biosciences’s named executive officers, FY2021
as the company reported each| Named executive officer | Role | FY2021 total |
|---|---|---|
| Rachel Haurwitz | President and chief executive officer | $6,249,919 |
| Jason O'Byrne · this page | Chief financial officer | $3,449,030 |
| Barbara McClung | Chief legal officer and corporate secretary | $2,743,054 |
The full Caribou Biosciences compensation record
free company briefThis page is one person within Caribou Biosciences's record. The company brief lists every named executive, each linking to their own page.
Compensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Caribou Biosciences's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.